FOR HEALTHCARE PROFESSIONALS ONLY

This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.

This site is produced by Roche as a partner of Roche Foundation Medicine.

!
We use cookies to help provide you with a better service. You can change your cookie settings at any time. Otherwise, we will assume you're OK to continue.
×
Menu
Close
orange
Šta je precizna medicina? Sveobuhvatno gensko profiliranje
Jump to a section

Inovativan pristup sveobuhvatnom genskom testiranju

Naš pristup

Foundation Medicine detaljno ispituje genom tumora

Foundation Medicine za sveobuhvatno gensko testiranje koristi tehnologiju sekvenciranja nove generacije (NGS) kako bi se analizirale regije tumorskog genoma koje ostali testovi izostavljaju. Sveobuhvatno gensko testiranje otkriva četiri glavne  vrste genskih promjena - supstituciju baza, insercije ili delecije, promjene broja kopija i  rearanžmane gena u setu gena za koje se zna da su značajni za razvoj raka. Također, određuje se i  mutacijsko opterećenje tumora (eng. tumor mutational burden, TBM)  te mikrosatelitska nestabilnost (eng. microsatellite instability, MSI).*1–6

Po čemu je sveobuhvatno gensko testiranje drugačije?

Jasni detaljni izvještaji

Izvještaj uključuje lijekove koji su odobreni od strane Američke agencije za hranu i lijekove (FDA)

Naš jasan, detaljan izvještaj uključuje informacije o klinički važnim genskim promjenama u tumoru oboljelog, moguće ciljane terapijske opcije i dostupna klinička ispitivanja. Izvještaj također naglašava važne gene povezane s nastankom bolesti  koji nemaju prepoznatljive  genske promjene te su povezani s mogućom rezistencijom na terapiju, te na taj način isključuju primjenu potencijalno neučinkovite terapije. 13   

Pogledajte primjer izvještaja:
FoundationOne CDx FoundationOne CDx
FoundationOne Liquid FoundationOne Liquid
FoundationOne Heme FoundationOne Heme

References
  1. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed March 2019).
  2. FoundationOne®Liquid Technical Specifications, 2018. Available at: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (Accessed March 2019).
  3. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).
  4. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  5. Clark TA et al. J Mol Diagn 2018; 20: 686–702.
  6. He J et al. Blood 2016; 127: 3004–3014.
  7. Suh JH et al. Oncologist 2016; 21: 684–691.
  8. Chalmers ZR et al. Genome Med 2017; 9: 34.
  9. Rozenblum AB et al. J Thorac Oncol 2017; 12: 258–268.
  10. Schrock AB et al. Clin Cancer Res 2016; 22: 3281–3285.
  11. Ross JS et al. Gynecol Oncol 2013; 130: 554–559.
  12. Hall MJ et al. J Clin Oncol 2016; 34: 1523–1523.
  13. FoundationOne®CDx Sample Report, 2018. Available at: www.rochefoundationmedicine.com/reporting (Accessed March 2019).
  14. A search for “Foundation Medicine”[Affiliation] on the NCBI database resulted in 321 publications, as of October 2018. Available at: https://www.ncbi.nlm.nih.gov/pubmed/term=%E2%80%9CFoundation+Medicine%E2%80%9D%5BAffiliation%5D (Accessed March 2019).
  15. Foundation Medicine Publications. Available at: https://www.foundationmedicine.com/publications (Accessed March 2019).
  16. FoundationOne®CDx FDA Approval, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed March 2019).
  17. FoundationOne®CDx clinical validation, 2017. Available at: http://www.foundationmedicine.com/genomic-testing/foundation-one-cdx (Accessed March 2019).